AC Immune to Showcase Anti Tau Portfolio at H C Wainwright 22nd Annual Global Investment Conference

LAUSANNE, Switzerland, Sept. 11, 2020 (GLOBE NEWSWIRE) -- AC Immune SA (NASDAQ: ACIU), a Swiss-based, clinical-stage biopharmaceutical company with a broad pipeline focused on neurodegenerative diseases, today announced that it will showcase recent progress in its clinical programs targeting Tau for neurodegenerative diseases at the upcoming H.C. Wainwright 22ndAnnual Global Investment Conference.

AC Immune CEO Prof. Andrea Pfeifer, Ph.D., will discuss the Company’s comprehensive anti-Tau clinical pipeline, which leads the industry in addressing this important neurodegenerative pathology. The extent of Tau pathology correlates very strongly with clinical decline throughout the course of disease, and AC Immune’s three clinical-stage therapeutic assets - an antibody, a small molecule inhibitor, and a vaccine - collectively target the full spectrum of Tau pathology by inhibiting both early intracellular Tau aggregation and extracellular seeding and spreading of pathological Tau protein. Prof. Pfeifer will also discussrecently publishedresults demonstrating the ability of its differentiated Tau positron emission tomography (PET) imaging agent PI-2620, which was discovered in a research collaboration with Life Molecular Imaging, to potentially facilitate an earlier and more reliable diagnosis of patients with progressive supranuclear palsy (PSP).

H.C. Wainwright 22ndAnnual Global Investment ConferenceDate: September 15, 2020 | 10:00–10:20 am ET / 4:00–4:20 pm CETFormat: Virtual Presentation followed by Q&APresenter: Prof. Andrea Pfeifer, CEO, AC Immune SA

The presentation will be followed by a question and answer session. A webcast of the presentation and Q&A will be available on theEvents Pageof AC Immune’s website.

About AC Immune SAAC Immune SA is a Nasdaq-listed clinical-stage biopharmaceutical company, which aims to become a global leader in precision medicine for neurodegenerative diseases. The Company utilizes two proprietary platforms, SupraAntigen™ and Morphomer™, to design, discover and develop small molecule and biological therapeutics as well as diagnostic products intended to diagnose, prevent and modify neurodegenerative diseases caused by misfolding proteins. The Company's pipeline features nine therapeutic and three diagnostic product candidates, with six currently in clinical trials. It has collaborations with major pharmaceutical companies including Genentech, a member of the Roche Group, Eli Lilly and Company and Janssen Pharmaceuticals.

This press release contains statements that constitute “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Forward-looking statements are statements other than historical fact and may include statements that address future operating, financial or business performance or AC Immune’s strategies or expectations. In some cases, you can identify these statements by forward-looking words such as “may,” “might,” “will,” “should,” “expects,” “plans,” “anticipates,” “believes,” “estimates,” “predicts,” “projects,” “potential,” “outlook” or “continue,” and other comparable terminology. Forward-looking statements are based on management’s current expectations and beliefs and involve significant risks and uncertainties that could cause actual results, developments and business decisions to differ materially from those contemplated by these statements. These risks and uncertainties include those described under the captions “Item 3. Key Information – Risk Factors” and “Item 5. Operating and Financial Review and Prospects” in AC Immune’s Annual Report on Form 20-F and other filings with the Securities and Exchange Commission. These include: the impact of Covid-19 on our business, suppliers, patients and employees and any other impact of Covid-19. Forward-looking statements speak only as of the date they are made, and AC Immune does not undertake any obligation to update them in light of new information, future developments or otherwise, except as may be required under applicable law. All forward-looking statements are qualified in their entirety by this cautionary statement.